TITLE:
      Alternate-Day Buprenorphine Administration. Phase IV - 5
SUMMARY:
      The purpose of this study is to determine if three times a subject's daily maintenance dose
      will hold for 72 hours without changes in agonist and antagonist effects.
ELIGIBILITY CRITERIA:
      Please contact site for information.
